Effect of concanavalin A on immunologic abnormalities of New Zealand (NZB/W) mice.
The administration of Concanavalin A (Con A) to young New Zealand (NZB/W) mice has been previously found to render them tolerable to BGG. The corresponding mechanism is unknown but is consistent with other observations that Con A is capable of activating a suppressor T cell population. We have further explored this possibility by giving New Zealand mice Con A from 1 month until 11 months of age and monitoring several known immunologic abnormalities. Con-A-treated mice, in contrast to littermate controls, were found to have lower anti-DNA levels, less proteinuria, a better response to primary sheep red cell immunization and normally rejected skin allografts.
D000367:Age Factors; D000818:Animals; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects*; D000941:Antigens; D003208:Concanavalin A / Q000494:pharmacology*; D004247:DNA; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006084:Graft Rejection / Q000187:drug effects; D006462:Hemolytic Plaque Technique; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008814:Mice, Inbred NZB / Q000276:immunology*; D011507:Proteinuria / Q000517:prevention & control; D012756:Sheep / Q000276:immunology; D016038:Skin Transplantation; D014181:Transplantation Immunology / Q000187:drug effects*; D014184:Transplantation, Homologous
D000906:Antibodies; D000941:Antigens; D003208:Concanavalin A; D004247:DNA